Hanmi Pharmaceutical to Operate Exclusive Booth at CPHI... Showcasing R&D and CDMO Capabilities

Hanmi Pharmaceutical announced on the 23rd that it will participate in the pharmaceutical exhibition 'Convention on Pharmaceutical Ingredients (CPHI) 2023' held in Barcelona, Spain, from the 24th to the 26th (local time).

Hanmi Pharm's CPHI booth. [Photo by Hanmi Pharm]

CPHI is the world's largest pharmaceutical and bio exhibition held annually across major European countries. This year, it is expected to attract more than 45,000 attendees from over 2,500 pharmaceutical and bio companies from 170 countries worldwide.

At this event, Hanmi Pharmaceutical, which has prepared a solo booth, will introduce its self-developed blockbuster products such as Rosuzet, Amozalatan, and Esomezol. At the same time, it plans to showcase more than 30 innovative new drug pipelines currently in operation in the fields of metabolic diseases such as obesity, oncology, and rare diseases.

Additionally, Hanmi Pharmaceutical will promote its advanced large-scale manufacturing facilities at the Pyeongtaek Bio Plant (bioreactors with a maximum capacity of 12,500 liters), along with specialized personnel and systems capable of operating them, and will engage in contract development and manufacturing organization (CDMO) order acquisition activities.

A Hanmi Pharmaceutical official stated, "We plan to solidify our position on the global stage by leading with products that have unique research and development (R&D) capabilities and differentiated competitiveness, while actively promoting the manufacturing capabilities of the Pyeongtaek Bio Plant, which meets global standards, to potential clients."

This content was produced with the assistance of AI translation services.